Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
NCT02161679 · Gilead Sciences · PHASE2 · withdrawn · last registry update 2021-08-19 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol we only drafted it to get the IND open - never initiated” | – | Registry record, Gilead Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TACSTD2 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-19Phase 3 first posted: Gilead Sciences, Sacituzumab Govitecan-hziy + Paclitaxel (NCT05382299)
- 2022-05-19Phase 3 first posted: Gilead Sciences, Sacituzumab Govitecan-hziy + Pembrolizumab (NCT05382286)
- 2022-05-16Phase 3 first posted: AstraZeneca, Dato-DXd + Paclitaxel (NCT05374512)
- 2022-02-08Also stopped (withdrawn): Veru Inc., Sabizabulin + Sacituzumab Govitecan-hziy (NCT05008510)
- 2021-11-03Phase 3 first posted: AstraZeneca, Dato-DXd + Capecitabine (NCT05104866)
- 2021-04-30Results posted on the registry: Gilead Sciences, Sacituzumab govitecan + Eribulin (NCT02574455)
- 2020-11-23Phase 3 first posted: Gilead Sciences, Sacituzumab Govitecan-hziy + Eribulin Mesylate Injection (NCT04639986)
- 2020-10-20Phase 3 first posted: GBG Forschungs GmbH, Capecitabine + Carboplatin (NCT04595565)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision